A double-blind, placebo-controlled study with A-2 on symptoms of vaginal atrophy in postmenopausal women

A double-blind, placebo-controlled study with A-2 on symptoms of vaginal atrophy in postmenopausal women - Effect of A-2 on symptoms of vaginal atrophy in postmenopausal women

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031295

Enrollment

Registered

2021-05-01

Start date

2018-02-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy postmenopausal women

Interventions

1 time or 2 times/day, for 12 weeks 1 time or 2 times/day, for 12 weeks

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Duration of amenorrhea; >2 y and <5 y 2) Serum estradiol concentration; <21 pg/mL 3) Serum FSH concentration; >30 mIU/mL 4) The symptoms of vaginal atrophy 5) BMI; >18.5 and <30 kg/m2 6) No medication for menopausal symptoms 7) No OTC medical agents or health foods for relief of menopausal symptoms

Exclusion criteria

Exclusion criteria: 1) Diversity from normal ranges of vital signs, and in clinical laboratory tests 2) Current or past reproductive-related cancer and so forth 3) Serious illumes 4) Allergies to soy or lactose 5) Individuals who are diagnosed as inappropriate for the trial by the principal Investigator

Design outcomes

Primary

Measure	Time frame
The symptoms of vaginal atrophy after ingestion for 12 weeks	—

Countries

Japan

Contacts

Public ContactShigeto Uchiyama

Otsuka Pharmaceutical Co., Ltd. Saga Nutraceuthicals Research Institute

Uchiyama.Shigeto@otsuka.jp0952-52-1522

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026